The C3⁺ subscription is subject to the attached Subscription Agreement.
Undiagnosed atrial fibrillation (VHF) increases the risk of stroke by a factor of 5.1 This risk can be reduced by early diagnosis and timely treatment.1 Innovative technologies such as C3+ can simplify and accelerate the diagnosis of VHF¹.
The C3+ records a high-quality 3-channel ECG signal, is lightweight, comfortable, reusable and has a battery life of 7 days.
The C3+ requires no cables, can be used with standard electrodes and offers both the physician and the patient a wireless Holter monitoring experience.
In addition, the C3+ integrates with two third-party analysis software programs that can be used either as stand-alone or cloud-based solutions.